QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)
QQQ   444.01 (-0.18%)
AAPL   171.48 (-1.06%)
MSFT   420.72 (-0.17%)
META   485.58 (-1.68%)
GOOGL   150.93 (+0.04%)
AMZN   180.38 (+0.31%)
TSLA   175.79 (-2.25%)
NVDA   903.56 (+0.12%)
NIO   4.50 (-3.64%)
AMD   180.49 (+0.50%)
BABA   72.36 (+1.08%)
T   17.60 (+0.28%)
F   13.28 (+1.68%)
MU   117.89 (-1.14%)
CGC   8.63 (-9.63%)
GE   175.53 (-2.55%)
DIS   122.36 (+1.14%)
AMC   3.72 (-14.29%)
PFE   27.75 (-0.11%)
PYPL   66.99 (+0.63%)
XOM   116.24 (+1.10%)

Omega Therapeutics (OMGA) Stock Price, News & Analysis

$3.65
+0.10 (+2.82%)
(As of 04:00 PM ET)
Today's Range
$3.59
$3.77
50-Day Range
$3.32
$4.33
52-Week Range
$1.30
$10.09
Volume
274,990 shs
Average Volume
2.22 million shs
Market Capitalization
$201.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Omega Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
227.0% Upside
$12.00 Price Target
Short Interest
Bearish
19.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.89mentions of Omega Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.93) to ($1.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.07 out of 5 stars

Medical Sector

632nd out of 938 stocks

Biological Products, Except Diagnostic Industry

108th out of 154 stocks

OMGA stock logo

About Omega Therapeutics Stock (NASDAQ:OMGA)

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

OMGA Stock Price History

OMGA Stock News Headlines

OMGA Apr 2024 12.500 call
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Omega Therapeutics: The Next Weight Loss Drug Runner
Omega Therapeutics Inc OMGA
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
OMGA Feb 2024 2.500 call
Why Is Omega Therapeutics (OMGA) Stock Up 111% Today?
Novo Nordisk Enters Collaboration Agreements With Omega And Cellarity
See More Headlines
Receive OMGA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omega Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:OMGA
Fax
N/A
Employees
116
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+238.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-102,700,000.00
Net Margins
-3,802.89%
Pretax Margin
-3,802.89%

Debt

Sales & Book Value

Annual Sales
$2.07 million
Book Value
$2.21 per share

Miscellaneous

Free Float
23,711,000
Market Cap
$195.75 million
Optionable
Optionable
Beta
1.88
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Mahesh Karande (Age 50)
    President, CEO & Board Director
    Comp: $812.88k
  • Ms. Ling Zeng Esq. (Age 55)
    J.D., Chief Legal & Administrative Officer and Secretary
    Comp: $519.36k
  • Dr. Yan Moore M.D. (Age 57)
    Chief Medical Officer
    Comp: $1.14M
  • Mr. Joshua Reed M.B.A. (Age 50)
    Chief Financial Officer
  • Dr. Sivakesava Sakhamuri Ph.D.
    Senior VP and Head of Technical Operations & Quality
  • Dr. Thomas McCauley (Age 55)
    Chief Scientific Officer
    Comp: $588.5k
  • Mr. Anthony Mullin
    Chief People Officer
  • Mr. Charles O'Donnell Ph.D.
    VP and Head of Computational Genomics & Data Sciences

OMGA Stock Analysis - Frequently Asked Questions

Should I buy or sell Omega Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Omega Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OMGA shares.
View OMGA analyst ratings
or view top-rated stocks.

What is Omega Therapeutics' stock price target for 2024?

3 analysts have issued 12-month target prices for Omega Therapeutics' shares. Their OMGA share price targets range from $12.00 to $12.00. On average, they predict the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 227.0% from the stock's current price.
View analysts price targets for OMGA
or view top-rated stocks among Wall Street analysts.

How have OMGA shares performed in 2024?

Omega Therapeutics' stock was trading at $3.01 at the start of the year. Since then, OMGA shares have increased by 21.9% and is now trading at $3.67.
View the best growth stocks for 2024 here
.

When is Omega Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our OMGA earnings forecast
.

How were Omega Therapeutics' earnings last quarter?

Omega Therapeutics, Inc. (NASDAQ:OMGA) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.09. Omega Therapeutics had a negative trailing twelve-month return on equity of 107.79% and a negative net margin of 3,802.89%.

When did Omega Therapeutics IPO?

Omega Therapeutics (OMGA) raised $126 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share.

Who are Omega Therapeutics' major shareholders?

Omega Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.74%), Vanguard Group Inc. (2.74%), Blue Owl Capital Holdings LP (1.91%), Northern Trust Corp (0.36%), Barclays PLC (0.09%) and Murphy Pohlad Asset Management LLC (0.03%). Insiders that own company stock include Flagship Pioneering Inc and Richard A Young.
View institutional ownership trends
.

How do I buy shares of Omega Therapeutics?

Shares of OMGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OMGA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners